TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2007) and:~* a) Smoking history of at least 10 pack-years~* b) Post-bronchodilator forced expiratory volume in 1 second (FEV1) \< 80% and ≥ 30% of the predicted normal value~* c) Post-bronchodilator FEV1/FVC (forced vital capacity) \< 70%~Exclusion Criteria:~* Patients who have received systemic corticosteroids or antibiotics and/or was hospitalized for a COPD exacerbation in the 6 weeks prior to screening~* Patients who have had a respiratory tract infection within 6 weeks prior to screening~* Patients with concomitant pulmonary disease~* Patients with a history of asthma~* Patients with diabetes Type I or uncontrolled diabetes Type II~* Any patient with lung cancer or a history of lung cancer~* Patients with a history of certain cardiovascular comorbid conditions~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 150 µg (Type: EXPERIMENTAL): Participants received indacaterol 150 μg delivered via a single-dose dry-powder inhaler (SDDPI) plus placebo to tiotropium delivered via the manufacturer's proprietary inhalation device (HandiHaler®) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
- Tiotropium 18 µg (Type: ACTIVE_COMPARATOR): Participants received tiotropium 18 μg delivered via the manufacturer's proprietary inhalation device (HandiHaler®) plus placebo to indacaterol delivered via a single-dose dry-powder inhaler (SDDPI) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
patients receiving tacrolimus for the treatment of lupus nephritis

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tacrolimus group (Type: None): Oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trivalent Chromium Treatment for Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* rheumatoid arthritis~Exclusion Criteria:~* other autoimmune diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Trivalent chromium (Type: ACTIVE_COMPARATOR): A dietary supplement already available in market one of its known uses is to control diabetes.
- Immunesuppressants (Type: ACTIVE_COMPARATOR): Synthetic and/ or biological DMARDs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females aged 18-65 years, inclusive~2. ≥10 cigarettes per day with no period of abstinence longer than 3 months in the past year and who are motivated to quit smoking~3. Able to give signed informed consent~4. Eligible female patients will be:~   1. non-pregnant~  2. non-lactating~  3. agree to use an acceptable method of effective contraception during the study~5. Eligible male patients agree to use contraception when sexually active with a female partner who is not using an acceptable method of birth control~6. Body weight of ≥50 kg (110 pounds), inclusive~7. Considered to be in stable health in the opinion of the investigator~Exclusion Criteria:~Patients who meet any of the following criteria will be excluded from the study.~1. Prior or current use of lorcaserin HCl~2. Prior participation in any study of a nicotine vaccination~3. Use of other therapies for smoking cessation is not allowed within 3 months of screening through study exit~4. Use of tobacco products other than cigarettes~5. Prior use of fenfluramine or dexfenfluramine~6. Serious or unstable medical condition or clinically significant new illness within the 6 months prior to screening~7. Previous participation in any clinical study within 6 weeks prior to the screening visit~8. History of severe allergies, severe drug or excipient allergy or hypersensitivity~9. History of significant cardiovascular condition~10. History of other significant medical conditions~11. Significant risk of suicide~12. Anticipated use of any agents that are associated with valvulopathy and/or pulmonary hypertension~13. Positive test result for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C~14. Recent history of alcohol or drug/solvent abuse~15. Concurrent participation in the study by more than one member of the same household~16. Not suitable to participate in the study in the opinion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- APD356 10 mg b.i.d. (Type: EXPERIMENTAL): APD356 - lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
- APD356 10 mg q.d. (Type: EXPERIMENTAL): APD356 - lorcaserin hydrochloride 10 mg tablet administered once daily and one matching placebo tablet administered once daily for 12 weeks
- Placebo 10 mg b.i.d (Type: PLACEBO_COMPARATOR): Placebo tablet matching the APD356-lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* unresectable liver metastasis secondary to cancer of colon or rectum;~* scheduled for standard first line chemotherapy;~* ECOG performance score of 0 or 1;~* condition feasible for major abdominal surgery after first line treatment.~Exclusion Criteria:~* diagnosis of metastatic disease \>3 months prior to study entry;~* evidence of extrahepatic disease, diffuse peritoneal carcinosis or involvement of celiac lymph nodes;~* prior systemic or local treatment of metastatic disease;~* prior (neo)adjuvant chemotherapy/radiotherapy completed within 6 months prior to study entry;~* history or evidence of CNS disease unrelated to cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Audiobooks for Hearing Loss App as Auditory Training

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~\*Because of the COVID-19 Pandemic and low enrollment numbers for certain HL subgroups in the study, the effectiveness of the Audiobooks for Hearing Loss App was measured for the overall group.~Participants had to fall into one of the following five HL subgroups: (1) Adults with HA, moderate HL (41-55 dB); (2) Adults with HA, moderately-severe to severe HL (56 to 90 dB); (3) Adults with non-recent CI, post-lingually deaf; (4) Children, ages 9+, non-recent CI, pre-lingually deaf; and (5) Adults and Children, ages 9+, recent CI, post-lingually deaf. These five subgroups span broad ranges in terms of: (1) age (adults vs. children); (2) severity of hearing loss; (3) device used (HAs vs. Cis); (4) familiarity with device (recent vs. longer-term); and (5) onset of HL (pre-lingual vs. post-lingual. The team expects the highest efficacy for children and adults with recent CI who are post-lingually deaf; the lowest efficacy for adults with HA with either moderate of severe HL; and intermediate efficacy for children with non-recent CI who are pre-lingually deaf.~* speaking English as first language,~* and being able to read at least a first-grade level.~Exclusion Criteria:~* no suspicions of cognitive deficits or vision impairments that would interfere with system usage or invalidate usability assessment,~* no signs of external ear disease,~* and all participants will be tested with the Expressive One-Word Picture Vocabulary Test, 4th Edition (EOWPVT-4; Brownell 2000), normed for ages of 2 and older, and are required to score in the 15th percentile or better.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- HA and CI Users using Audiobooks for Hearing Loss for Auditory Training (Type: OTHER): study participants will be seen weekly for 12 weeks and will use the Audiobooks for HL App for the final 6 weeks using the App at least two hours per week on their own. The researcher will conduct 12 weekly in-home visits where the following will be done:~First 6 weeks:~• Partial BKB-SIN will be administered~Final 6 weeks:~* Partial BKB-SIN will be administered~* Conduct a comprehension test.~* Address any usability issues the participant brings up.~* Review and set new weekly goals Final session: Conduct Final Usability survey

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COPD diagnosis~* At least 10 pack year smoking history~* Post-albuterol FEV1 greater than or equal to 40% to less than or equal to 80% of predicted normal~* An FEV1/FVC ratio of less than or equal to 0.70~Exclusion Criteria:~* Current diagnosis of asthma~* Other respiratory disorder other than COPD~* Abnormal and clinical significant ECG~* Chest x-ray clinically significant abnormality not believed to be due to COPD~* Body Mass Index of greater than or equal to 40/kg/m2~* Use of Long Term Oxygen Therapy~* Lung resection surgery~* Women pregnant or lactating at Visit 1~* Previously diagnosed cancer unless in complete remission for 2 years at Visit 1

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler (Type: EXPERIMENTAL): Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Plus Tiotropium Bromide 18 mcg QD
- SPIRIVA® HANDIHALER® inhaler (Type: ACTIVE_COMPARATOR): Tiotropium Bromide 18mcg QD plus Placebo DISKUS BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Azithromycin Versus Doxycycline in Posterior Blepharitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients were diagnosed with posterior blepharitis if they scored at least one in two symptoms (based on a subjective grading scale) and two signs (based on an objective grading scale) of posterior blepharitis according to study criteria~Exclusion Criteria:~Patients were excluded if they had the following criteria: age\< 12 years old,history of previous ocular or lacrimal surgery,previous usage of contact lenses,any history of ocular allergy,history of systemic diseases with ocular involvement (except rosacea), history of usage of topical or systemic antibiotic in the last month, pregnancy or lactating mothers, liver failure and any history of sensitivity to cyclines

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Oral Azithromycin (Type: EXPERIMENTAL): Two 250 mg capsules (500 mg) of Azithromycin for the first day and 250mg/day for the next 4 days.
- Doxycycline (Type: ACTIVE_COMPARATOR): Oral doxycycline 100mg capsule every 12 hours for one month

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Histologically confirmed stage III (unresectable) or stage IV melanoma~* Treatment naïve patients~* Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria~* Tumor tissue from an unresectable or metastatic site of disease for biomarker analyses~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1~Exclusion Criteria:~* Active brain metastases or leptomeningeal metastases~* Ocular melanoma~* Subjects with active, known or suspected autoimmune disease~* Subjects with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment~* Prior treatment with an anti-Programmed Death receptor-1 (PD-1), anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, or anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) antibody

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab (Type: EXPERIMENTAL): Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Ipilimumab 0 mg/kg solution intravenously on weeks 1, 4 and Placebo matching with Nivolumab on weeks 4 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
- Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab (Type: EXPERIMENTAL): Nivolumab 1 mg/kg solution intravenously combined with Ipilimumab 3 mg/kg solution intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Nivolumab on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
- Arm C: Ipilimumab+Placebo for Nivolumab (Type: EXPERIMENTAL): Ipilimumab 3 mg/kg solution intravenously every 3 weeks for a total of 4 doses plus Placebo matching with Nivolumab 0 mg/kg solution intravenously on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends (Placebo matching with Nivolumab is no longer required)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of G-CSF for the Treatment of Unexplained Recurrent Miscarriage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* four or more previous consecutive abortion,~* failed previous treatment with intravenous immunoglobulins~* negative to all clinical investigation for recurrent miscarriage~Exclusion Criteria:~* in the last abortion a fetal karyotype showing chromosomal abnormality~* previous successful pregnancy

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Granulocyte colony stimulating factor (Type: EXPERIMENTAL): The G-CSF group of 35 women, underwent a daily sub-cutaneous administration of the filgrastim (Neupogen, Dompe', Italy), the recombinant G-CSF, at a dosage of 1 micro gram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
- placebo (saline solution) (Type: PLACEBO_COMPARATOR): The placebo group consisting of 33 subjects, was given a treatment with saline solution at the 0.2ml/day subcutaneously/, from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual Dosage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age older than 18 years~* HIV-1 infection~* Women of child-bearing age: negative pregnancy test~* Ability to understand and sign a written consent form~Exclusion Criteria:~* Pregnancy..~* Illegal drug or methadone use.~* Major psychiatric disease antecedents or starting new psychotropic agents in the last 4 weeks~* Concomitant treatment with rifamycins, protease inhibitors or drugs which interfere the pharmacokinetic of efavirenz.~* Hepatic insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B (Type: ACTIVE_COMPARATOR): None
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Willingness to sign a written informed consent~* Chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2009~* Chinese or Malay or Indian ethnicity~* History of chronic obstructive pulmonary disease symptoms for at least 12 months prior to baseline visit V0~* Forced expiratory volume in the first second/ Forced vital capacity (FEV1/FVC) ratio (post-bronchodilator) \< 70%~* Forced expiratory volume in the first second (FEV1) (post-bronchodilator) \< 50 % of predicted~* Former smoker (defined as: smoking cessation at least one year ago) or current smoker both with a smoking history of at least 10 pack years~Main Exclusion Criteria:~* Moderate or severe COPD exacerbation and/or COPD exacerbations treated with antibiotics not stopped at V0~* Lower respiratory tract infection not resolved 4 weeks prior to the baseline visit V0~* History of asthma diagnosis in patients \< 40 years of age or relevant lung disease other than COPD~* Current participation in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 3 months preceding the baseline visit V0~* Known alpha-1-antitrypsin deficiency

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: EXPERIMENTAL): Roflumilast 500 μg, tablet, oral, once daily for up to 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to roflumilast, tablet, oral, once daily for up to 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete